Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Condensed Consolidated Statements Of Operations        
Revenues, net $ 187,912 $ 457,780 $ 418,325 $ 733,245
Operating expenses:        
Cost of implants and other costs 46,185 108,750 86,638 120,250
Selling, general and administrative 553,224 465,325 944,463 703,393
Termination of licensing agreement 3,639,694 132,804 3,639,694
Loss on settlement of sub-licenses 118,027 118,027
Depreciation and amortization 795 33,723 1,368 67,289
Total operating expenses 600,204 4,365,519 1,165,273 4,648,653
Loss from operations (412,292) (3,907,739) (746,948) (3,915,408)
Other income (expenses):        
Interest expense, net (223,127) (62,805) (388,359) (162,654)
(Loss) gain on change in fair value of derivative liability (438,344) 199,824 (467,041) 104,168
Total other income (expenses) (661,471) 137,019 (855,400) (58,486)
Loss before income taxes (1,073,763) (3,770,720) (1,602,348) (3,973,894)
Income taxes
Net loss $ (1,073,763) $ (3,770,720) $ (1,602,348) $ (3,973,894)
Net loss per common share, basic and diluted $ (0.01) $ (0.02) $ (0.01) $ (0.03)
Weighted average number of common shares outstanding, basic and diluted 165,394,501 151,757,578 165,166,479 150,453,147